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http://dx.doi.org/10.1016/j.pedneo.2Background: Cysteinyl leukotrienes (CysLTs) play a major role in the pathogenic changes of
airway inflammation in asthma treatment. The matrix metalloproteinase (MMP) family, espe-
cially MMP-9 and MMP-2 levels, can reflect the status of airway remodeling. This study was
undertaken to determine the role of a specific CysLT receptor antagonist in inhibition of airway
inflammation and reversal of airway remodeling.
Methods: Ovalbumin (OVA)-sensitized BALB/c mice were fed with a specific leukotriene
receptor antagonist (MK-679), prednisolone or placebo from Days 15 to 27. Airway hyperreac-
tivity, bronchoalveolar lavage fluid (BALF), and sera were analyzed. Pulmonary histology was
obtained, and the levels of MMP-2 and MMP-9 in BALF were measured.
Results: The OVA-sensitized mice developed significant airway inflammatory responses,
including extensive eosinophils trafficking into BALF and lung interstitium, goblet cell hyper-
plasia, mucus hypersecretion, elevated serum immunoglobulin (Ig) E, and decreased level of
serum IgG2a. Administration of MK-679 could reduce airway inflammation but was not as effec-
tive as prednisolone. However, MK-679 was more effective than prednisolone for reversingllergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital,
oad, Taichung 402, Taiwan, ROC.
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236 C.-H. Hsu et alsubepithelial fibrotic and myofibrotic reactions of airway remodeling. The levels of MMP-2 and
-9 in BALF were proportional to the extent of airway remodeling, which can reflect the effects
of treatment. Both prednisolone and MK-679 reverse airway hyperresponsiveness induced by
OVA-sensitized mice.
Conclusion: Cysteinyl leukotriene receptor plays a more important role than CysLT in the path-
ogenesis of allergic airway inflammation. MMP-2 and -9 may be more sensitive indicators of
airway remodeling.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Asthma has long been recognized as a complicated disease
that affects millions of people. It is first characterized by
airway hyperresponsiveness (AHR) to a variety of specific or
non-specific stimuli, mucus hypersecretion, pulmonary
eosinophilia, airway edema and elevated serum immuno-
globulin (Ig) E.1,2 After awhile, persistent allergen stimu-
lation induces chronic inflammatory changes in airways.
Airway remodeling is accompanied by subepithelial fibrosis,
fragmentation of elastic fibers, airway smooth muscle
thickening, goblet cell metaplasia, changes in airway
epithelium, and vascular hyperplasia.3,4 The major cause
that results in airway narrowing after remodeling is sub-
epithelial fibrosis. This striking change comes from the
deposition of extracellular matrix (ECM) proteins (e.g.,
collagen, fibronectin, laminin, tenascin) in the lamina
reticularis,3,5 which makes chronic asthma difficult to
control with inhaled b2 agonist only.
6e8 To date, there is
still no satisfactory therapy available to better control
asthma. The main issues to tackle in devising asthma
treatment is understanding how repeated airway inflam-
mation during asthma attacks results in airway remodeling,
and identifying the major cytokines involved in this
process. Cysteinyl leukotrienes (CysLTs) are now known as
a major cytokine that are involved in the pathogenic
changes of airway inflammation. They exert most of their
bronchoconstrictive and proinflammatory effects through
activation of a putative 7-transmembrane domain, G-pro-
teinecoupled CysLT1 receptor.
9 CysLTs are also the most
potent factors that aggravate airway remodeling through
the CysLT1 receptor.
9,10
It has been shown that administration of corticosteroids
during or after the allergen challenge period block the
airway inflammatory responses.5,11,12 However, the effect
of corticosteroid on airway remodeling is still controversial.
In some mouse asthma models, concomitant treatment of
corticosteroids during the allergen challenge period pre-
vented the development of structural changes, including
subepithelial fibrosis.13,14 However, others have reported
only limited14,15 or no effects5 on reversing the established
airway remodeling. In spite of the many challenges on
airway remodeling that corticosteroid can exert, it still
serves as the major agent in current asthma treatments. To
resolve the above issues, we aimed to determine the
effects of the selective CysLT receptor antagonist MK-679
(Verlukast), in comparison to those of the corticosteroid
prednisolone on airway remodeling in a chronic mouseasthma model. In this study, applications of therapeutic
agents were all by gavage, which is rarely performed by
other studies13 but may more closely reflect physiologic
conditions in daily life.
Matrix metalloproteinases (MMPs) are a family of extra-
cellular proteases that are responsible for degradation of
extracellular matrix during tissue remodeling.16 Among the
family of MMPs, the gelatinases MMP-2 and MMP-9 are
specific to denatured collagens and collagen-IV of the
basement membrane.17 Deposition of collagen over the
basement membrane is a predominant finding during peri-
bronchial fibrosis of airway remodeling.16 In all studies to
date, MMP-9 was thought to be the major MMP in the
airways of asthmatics. This suggests an important role of
MMP-9 during asthma treatment and monitoring of the
process of airway remodeling. In this study, we investigated
the expression of MMP-2 and MMP-9 in bronchoalveolar
lavage fluid (BALF) after treatment.
2. Methods
MK-679(R()-3-((3-(2-(7-chloro-2-quinolinyl)ethenyl)phe-
nyl)(3-(dimethylamino) -3-oxopropyl)thio)methyl)thio(-
propanoic acid) is a potent and specific LTD4-receptor
antagonist, selective inhibitor of [3H]leukotriene D4
binding. The binding site is different from that of popular
prescription of leukotriene receptor antagonist, Mon-
telukast. Otherwise, MK-679 had intravenous and inhaled
forms in the clinical trial. It is more convenient than other
medications for asthma control.18,19 The key reagent MK-
679 was provided by Merck Sharp & Dohme Corp. (One
Merck Drive, Whitehouse Station, NJ, USA).
2.1. Sensitization and airway challenge for
induction of airway remodeling
Female BALB/c mice, 6e8 weeks of age, were obtained
from the National Laboratory Animal Center (seven mice/
group). The mice were maintained on ovalbumin (OVA)-free
diets. The mice were immunized with intraperitoneal (IP)
injections of 100 mg OVA (0.2 ml of 0.5 mg/ml; grade V;
Sigma Chem. Co., St. Louis, USA) complexed with alum
(Sigma Chem. Co., St. Louis, USA) on Days 0 and 14.11,20 For
the age- and sex-matched control groups, the unsensitized
mice received an IP injection of 0.2 ml saline complexed
with alum. Intranasal (IN) OVA challenge was first admin-
istered with a dosage of 100 mg (0.05 ml of 2 mg/ml) on Day
Cysteinyl leukotriene receptor antagonists 23714. IN OVA challenges were then repeated on Days 25, 26,
and 27 with doses of 50 mg (0.05 ml of 1 mg/ml). Before the
intranasal challenge, the mice were first anesthetized with
IP 40 mg/kg sodium pentobarbital. For the control group,
the unsensitized mice received an IN normal saline of 50 ml
on Day 14 and Days 25, 26, and 27. In this mouse asthma
model, normal saline was used as a negative control.
2.2. Therapeutic intervention with leukotriene
receptor antagonist and corticosteroid
During Days 15 to 27, randomized treatment groups of mice
were respectively fed with different agents by gavage. A
group of OVA-treated mice was fed with selective leuko-
triene D4 receptor antagonist MK-679 (Verlukast, 60 mg/kg/
day, dissolved in apple juice; Merck Sharp and Dome Co.,
Inc.).21,22 The positive control group of mice was fed with
prednisolone sodium phosphate solution (3 mg/kg/day;
Center Laboratories, Inc., Taipei, Taiwan).12 A group of
unsensitized mice and a set of OVA-treated mice were given
apple juice as placebo.
2.3. Determination of airway responsiveness
by noninvasive pulmonary function test
On Day 28, 24 hours after the last intranasal challenge with
either normal saline or OVA, noninvasive pulmonary
mechanics were determined by whole-body plethysmog-
raphy (Model PLY 3211; Buxco Electronic Inc., Sharon, CT,
USA).23 Airway hyperreactivity to aerosolized methacholine
was performed in conscious, freely moving, spontaneously
breathing mice. Aerosol was first generated by placing
0.5 ml of saline or methacholine solution in the cup of an
ultrasonic nebulizer. Different concentrations of aero-
solized methacholine (0, 5, 10, and 20 mg/ml) were inhaled
in turn. The degree of bronchoconstriction was expressed
as enhanced pause (Penh), a calculated dimensionless
value that correlates with measurements of airway resis-
tance, impedance, and intrapleural pressure.
2.4. Immunoassay for serum IgE levels
After plethysmography, the mice were sacrificed; each
mouse was then exsanguinated by cardiac puncture. The
blood was transferred to a 2 ml microcentrifuge tube that
contained gel and then centrifuged at 4C, 6000 rpm for 5
minutes. Serum was removed and red blood cells were dis-
carded. The serumwas divided into three aliquots and stored
at 70C until antibody level analyses were performed.
Indirect enzyme-linked immunosorbent assay (ELISA) was
employed to determine IgE serum antibody titers. ELISA
plates with 96 wells (Alpha Diagnostics Intl Inc., San Antorio,
USA) were coated with anti-mouse IgE. All reagents in the
procedurewere allowed to reach room temperature. Twenty
microliters of standards and serum were added separately
with 80 ml of sample buffer in each well. After incubation for
60 minutes at room temperature, the plate was washed five
times. One hundred microliters of horseradish peroxidase
(HRP)-labeled anti-mouse IgE conjugate were added and
incubated at room temperature for 30 minutes, followed by
adding 100 ml of 3,30,5,50-Tetramethylbenzidine (TMB)substrate solution and incubating at room temperature for
15 minutes. After 100 ml of stop solution was added, optical
density (OD) readings of the samples were obtained from
measuring the absorbance at 450 nm by an ELISA reader. The
antibody titers of the samples were compared to pooled
standards that were generated in the laboratory and
expressed as nanogram per milliliter (ng/ml).
2.5. Acquisition of BALF and quantifization of BALF
cell level
BALF was done after sacrificed mice were exsanguinated.
The right lung was separated by ligating at the right main-
stem bronchus; BAL was performed on the left lung. The left
lung was lavaged three times with 0.5 ml of normal saline.
The first-collected BAL fluidwas centrifuged at 4C, 1000 g for
5minutes. The supernatant (about 400ml)was extractedand
divided into three equal portions, and then frozen at 80 C
for subsequent testing. The pellet was resuspended and
mixed gently with second-collected and third-collected BAL
fluid containingmicrocentrifuge tubes. Tenmicroliters of the
resuspendedBALFwas stainedwith 0.06%methylene blue for
total leukocyte count with a hemocytometer. Two hundred
microliters of diluted BAL cell suspension was aliquoted into
the single-chamber cytospin device in a cytocentrifuge
(Rotofix 32; Andreas Hettich GmbH & Co. KG, Tuttlingen,
Germany), followed by centrifuging a slide at room temper-
ature, 500 rpm for 4 minutes. The slide was stained with
hematoxylin and eosin stain to assess eosinophil counts.
Differential counts were performed in a blinded fashion by
counting at least 300 cells under light microscopy.
2.6. Measurement of matrix metalloproteinases
(MMP)-2 and MMP-9 activity
After bronchoalveolar lavage, the activity of MMP-2 and 9
was determined by gelatin zymography. Five microliters of
samples (BALF) were added to 4 ml of loading buffer and
separated by electrophoresis (140 V for 3 hours) in 8%
Sodium dodecyl sulfate (SDS)-polyacrylamide gels that
contained 0.1% gelatin. The (SDS) was removed by washing
gels twice with 50 ml washing buffer (2.5% Triton X-100
in d-H2O, Sigma Chem. Co. St. Louis, USA), each wash
lasting 30 minutes under room temperature. After incuba-
tion for 12 hours at 37C in reaction buffer, the gels were
stained with staining buffer (0.25% Coomassie Blue) for 30
minutes. The optical densities of the MMP-2, 9 bands were
quantified by densitometer (AlphaImager 2000, Alpha
Innotech Corporation, San Leandro, CA, USA). Results were
expressed as zymography activity (relative density) on the
basis of the computer analysis. An MMP-2 and MMP-9 stan-
dards were used as a positive control.
2.7. Lung histology
After BAL, trachea and right lung were obtained and fixed
in formalin at room temperature for about 15 hours. The
right lung tissue was then embedded in paraffin and cut into
5-mm sections. The lung sections were stained with hema-
toxylin and eosin to determine the airway inflammatory cell
infiltration and smooth muscle thickness. Each slide was
Figure 1 Effects of selective CysLT receptor blockade and
corticosteroid treatment on serum IgE levels in OVA-treated
mice. Concentration of serum IgE were obtained from saline-
treated mice and OVA-sensitized/challenged mice in the
absence or presence of treatment with prednisolone (3 mg/kg)
or MK-679 (60 mg/kg). The results are expressed as
means  SEM. N Z 7 in each group. *p < 0.05, compared with
all other groups. yp < 0.05, compared with the OVA-treated
sensitized group by analysis of variance. CysLT Z cysteinyl
leukotriene; Ig Z immunoglobulin; OVA Z ovalbumin.
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morphometric variation. To analyze the anatomic distri-
bution of collagen deposition/fibrosis in the airway, the
lung sections were stained with Masson’s trichrome stain.
The total area of Masson’s trichrome staining in each
paraffin embedded lung was outlined and quantified by
using a light microscope attached to an image analysis
system (Image-Pro Plus; Media Cybernetics, Silver Springs,
MD, USA). The unit area of captured images was calibrated
and standardized with a slide micrometer. Results were
expressed as the area of Masson’s trichrome staining per
micrometer length of basement membrane of bronchioles
(w150e200 mm of internal diameter, surrounded by smooth
muscle cells).16 Between three and five bronchioles were
counted in each slide. All slides were stained in the same
set under identical staining conditions and analyzed under
the same light microscope conditions. The lung tissue slides
for morphologic survey were coded and analyzed by tech-
nicians who were blind to the protocol design. Each slide
was also analyzed in the same predetermined sequence to
minimize observer bias.
2.8. Liver and kidney histology
Liver and kidney tissues of the MK-679-treated (60 mg/kg/
day) group were embedded in paraffin and cut into 5-mm
sections. The liver and kidney sections of the MK-679
treated group were stained with hematoxylin and eosin
for toxic effect screening and evaluation. There was no
pathogenic finding over the liver and kidney tissues of the
MK-679-treated group.24 Comparing the tissues with the
liver and kidney tissues from the saline-treated or OVA-
treated group, no specific difference was found.
2.9. Statistical analyses
The data were reported as mean  SEMs of the combined
experiments. Results in the different groups were
compared by analysis of variance (ANOVA) using the pro-
tected least significant difference method. Differences
between each group were considered statistically signifi-
cant when p values< 0.05.
3. Results
3.1. Effects of selective CysLT receptor antagonist
and corticosteroid treatment on reversal of
allergen-induced airway inflammation and
remodeling serum IgE production
Serum IgE level was elevated significantly in the OVA-
sensitized/challenged group compared with the saline-
treated control group (1615.71  403.59 ng/ml vs.
126.29  13.39 ng/ml; p < 0.001). This is shown in Figure 1.
Administration of both prednisolone (515.05  117.84 ng/
ml; p Z 0.001 vs. sensitized group) and MK-679
(501.75  96.42 ng/ml; p Z 0.001 vs. sensitized group) to
OVA-treated mice during repetitive ovalbumin challenges
had significant effects on inhibiting the serum IgE release.
Each respectively reduced the serum IgE level by 68.1%(steroid/OVA vs. OVA) and 68.9% (MK-679/OVA vs. OVA).
The serum IgE levels of OVA- sensitized/challenged mice
treated with prednisolone or MK-679 were not significantly
different from those of the saline control group.
3.2. Airway inflammatory cell infiltration
Airway inflammatory cells markedly infiltrated into BALF of
the OVA- sensitized/challenged group compared with the
saline-treated control group (11.29  1.94  105/ml vs.
1.71 0.52 105/ml; p< 0.001). This is shown in Figure 2A.
Administration of prednisolone to OVA-treated mice during
repetitive ovalbumin challenges had significant effects on
reducing infiltration of airway inflammatory cells into BALF
(3.43  0.65  105/ml; pZ 0.001 vs. sensitized group). By
contrast with the significant effects of prednisolone on
inhibiting airway inflammatory cells infiltrating into
BALF, the effects of MK-679 on reducing the levels of
BALF inflammatory cells were not significantly different with
the OVA-treated group (7.79  2.26  105/ml vs.
11.291.94105/ml;pZ 0.093). This is shown inFigure 2A.
However, there appeared to be a trend that MK-679 inhibited
the infiltration of airway inflammatory cells into BALF.
3.3. Eosinophilia in bronchoalveolar lavage fluid
The percentage of BALF eosinophils in OVA-treated mice
was significantly greater than in control saline-treated mice
(1.1  0.29% vs 48.29  4.48%; p < 0.001). This is shown in
Figure 2B. Although both prednisolone and MK-679 had
significant effects on reducing eosinophil influx into BALF
in OVA-treated mice, administration of prednisolone
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Figure 2 Effects of selective CysLT receptor blockade and
corticosteroid treatment on inflammatory cell infiltration
(A) and the percentage change of eosinophils (B) in BALF of
OVA-treated mice. BALF was obtained from saline-treated mice
andOVA- sensitized/challengedmice in the absence or presence
of treatment with prednisolone (3mg/kg) or MK-679 (60mg/kg).
The total cell counts (105) per ml of BALF and the percentage
of eosinophils (%) were determined bymorphometric evaluation
of cytospin preparations. MK-679-treated group had no signifi-
cant effects on decreasing total cell counts in BALF. The results
are expressed as means  SEM. NZ 7 in each group. *p < 0.05,
compared with the saline-treated control group. yp < 0.05,
compared with the OVA-treated sensitized group by analysis of
variance. BALF Z bronchoalveolar lavage fluid; CysLT Z
cysteinyl leukotriene; OVAZ ovalbumin.
Cysteinyl leukotriene receptor antagonists 239(20.29  7.98%; p Z 0.003 vs. sensitized group) during
repetitive ovalbumin challenges seemed to be more
effective than MK-679 (30.76  7.81%; p Z 0.05 vs. sensi-
tized group) on reducing eosinophils in BALF.
3.4. Airway goblet cell metaplasia and smooth
muscle cell layer thickening
Cross-sections of the right lungs of OVA-treated and saline-
treated control mice were examined by light microscopy forgoblet cells and smooth muscle cells hyperplasia in the
airways (Figures 3A and 4A). By morphometric analysis, no
evidence of goblet cell proliferation or airway muscle layer
thickening was observed between controls. In contrast,
OVA-treated mice had morphologic evidence for wide-
spread goblet cell hyperplasia (Figure 4B) and muscle layer
thickening (Figure 3B) of the airways. Goblet cell hyper-
plasia of OVA-sensitized/challenged mice airways was not
effectively blocked by prednisolone treatment, which was
demonstrated by Masson’s trichrome stain (Figure 4B vs.
4C). Neither could treatment with prednisolone totally
reverse the thickened airway smooth muscles of OVA
sensitized/challenged mice (Figure 3C vs. 3B), as shown by
hematoxylin and eosin stainings. However, MK-679 effec-
tively blocked the development of airway goblet cell
metaplasia and smooth muscle layer thickening in OVA-
treated mice (Figures 3D and 4D).
3.5. Airway collagen deposition and peribronchial
fibrosis
The area of collagen deposition/fibrosis was assessed by
Masson’s trichrome stain. Collagen deposition was markedly
increased over perivascular and lung interstitium around
airways in OVA-sensitized/challenged mice compared with
the saline-treated control group (Figure 4A vs. 4B). This
increase in airway collagen deposition could be reversed by
prednisolone or MK-679 administered during OVA challenge
(Figure 4C and D). The area of peribronchial trichrome
staining in OVA-treated mice was significantly greater than
that in control saline-treated mice (3.28  0.28 vs
0.19  0.03 mm2/mm circumference of bronchiole;
p < 0.001). This is shown in Figure 5. Administration of
either prednisolone (0.98  0.37 mm2/mm circumference of
bronchiole; p < 0.001 vs sensitized group) or MK-679
(0.38  0.18 mm2/mm circumference of bronchiole;
p < 0.001 vs sensitized group) to sensitize mice significantly
reduced the area of peribronchial trichrome staining. No
statistical difference in peribronchial fibrosis was observed
between the control group and the OVA-treated with MK-
679 administered group. However, there was statistical
difference between the control group and the OVA-treated
with prednisolone administered group (0.79 mm2/mm
circumference of bronchiole; p Z 0.02). The effect of
peribronchial fibrosis reversal was greater after adminis-
tration of MK-679 compared with prednisolone.
3.6. Detection of MMP-2 and MMP-9 activity in BALF
Quantitative analysis of MMP-2 and MMP-9 expression by
zymography demonstrated minimal expression of either
MMP-2 (168.63  27.88 relative density) or MMP-9
(19.92  2.94 relative density) in BALF (Figure 6) of
saline-treated mice. In contrast, both levels of MMP-2
(284.27  43.44 relative density; p Z 0.006 vs. control
group) and MMP-9 (333.29  15.79 relative density;
p < 0.001 vs. control group ) in BALF (Figure 6) were
significantly increased after repetitive ovalbumin challenge
in the remodeled airway. Levels of MMP-2 and -9 inhibition
were induced by both prednisolone and MK-679. Adminis-
tration of prednisolone to OVA-treated mice significantly
Figure 3 Effects of selective CysLT receptor blockade and corticosteroid treatment on allergen-induced airway inflammation and
remodeling. Lung tissues were obtained on Day 28 from saline controls (A) and OVA-treated mice in the absence (B) or presence of
prednisolone (C) or MK-679 (D) and stained with hematoxylin and eosin. (A) Scarcity of inflammatory cells around the airway in
saline-treated controls. (B) Large amounts of inflammatory cells (arrow) are identified over peribronchial tissues of OVA-treated
mice. Thickening of airway smooth muscle layer (arrowhead ) is also noted in this group. (C, D) Massive infiltration of inflamma-
tory cells and hyperplasia of airway smooth muscle layer were markedly reduced by either prednisolone or MK-679 given during
repetitive OVA challenges. CysLT Z cysteinyl leukotriene; OVA Z ovalbumin.
240 C.-H. Hsu et alreduced the level of MMP-2 (113.08  7.29 relative density;
p < 0.001 vs. sensitized group) and MMP-9 (38.46  5.57
relative density; p < 0.001 vs. sensitized group). This is
shown in Figure 6B and C. Applying MK-679 to OVA-treated
mice could also reduce the level of MMP-2 (76.74  11.33
relative density; p < 0.001 vs. sensitized group) and MMP-9
(98.24  8.84 relative density; p < 0.001 vs. sensitized
group) significantly (Figure 6B and C). However, the levels
of MMP-9 inhibition were, in general, greater after admin-
istration of prednisolone compared with administration of
MK-679 (p Z 0.003).
3.7. Effects of selective CysLT receptor antagonist
and corticosteroid treatment on allergen-induced
airway hyperreactivity to methacholine
noninvasive in vivo plethysmography
Airway reactivity to aerosolized methacholine was evalu-
ated on Day 28, 24 hours after the last intranasal challenge
with OVA or saline, by noninvasive plethysmography
(Figure 7). Penh (% of air) was significantly increased in the
OVA-treated mice compared with saline controls after
challenged with methacholine at 5 mg/ml (pZ 0.008, OVAvs. saline; Figure 7A). However, at higher doses (10 and
20 mg/ml), no significant increases were seen in Penh in
OVA-treated mice compared with the saline group
(Figure 7B). Administration of prednisolone or MK-679 was
similar in low-dose methacholine challenge conditions, in
that Penh was significantly reduced in prednisolone/OVA
(p Z 0.031, OVA vs. prednisolone/OVA; Figure 7A) and MK-
679/ OVA (pZ 0.05, OVA vs. MK-679/OVA; Figure 7A) group
after methacholine challenge at 5 mg/ml. By contrast,
after higher doses (10 and 20 mg/ml) of methacholine
challenge, administration of prednisolone or MK-679 did not
significantly change the airway responses to methacholine
in OVA-sensitized/challenged mice (Figure 7B). The MK-679
even failed to reduce airway hyper-reactivity to 10 and
20 mg/ml of aerosolized methacholine in OVA sensitized/
challenged mice.
4. Discussion
We employed an allergen-induced airway inflammatory
model in mice to address the role of cysteinyl leukotrienes
(CysLTs) in mediating pulmonary inflammation, which
promotes airway remodeling and hyperreactivity to
Figure 4 Effect of selective CysLT receptor blockade and corticosteroid treatment on allergen-induced goblet cell hyperplasia
and collagen deposition/fibrosis. Lung tissues were obtained on Day 28 from saline controls (A) and OVA-treated mice in the
absence (B) or presence of prednisolone (C) or MK-679 (D) and stained with Masson’s trichrome stain. (A) The airway is clear of
mucus in lumen and fewer collagen depositions in saline-treated controls. (B) Accumulation of mucus (*) in the airway lumen is
observed. Large amounts of collagen deposition (arrow) are identified around perivascular and peribronchial tissue of OVA-treated
mice. Many goblet cells (arrowheads) are seen in the airway. (C) Extensive collagen (arrow) deposition and goblet cells (arrow-
heads) hyperplasia are still noted in prednisolone-treated mice. (D) The dense collagen depositions and abundant goblet cells were
reduced after MK-679 treatment compared to the OVA-treated group. CysLT Z cysteinyl leukotriene; OVA Z ovalbumin.
Cysteinyl leukotriene receptor antagonists 241methacholine. The levels of serum IgE and airway inflam-
matory cells, including eosinophils, can be suppressed by
corticosteroid during allergen challenge. However, in our
study, intervention with MK-679 did not as function well as
corticosteroid on inhibiting serum IgE release and eosino-
phil infiltration. This may be due to MK-679 having limited
effects in acute airway inflammation.
In vitro studies showed that CysLTs induced release of
collagen and fibroblast growth factors from mouse alveolar
macrophages.25,26 Alveolar macrophages can also express
MMPs after repeated ovalbumin challenge.16 MMPs, espe-
cially MMP-9 and MMP-2, are known to regulate collagen
synthesis and breakdown, which can then promote airway
remodeling.17 Since alveolar macrophages express LTD4
high-affinity receptors, blocking the receptors by a potent
and selective LTD4 receptor antagonist, Verlukast (MK-
679),9,27 may inhibit the positive cycles of collagen release.
A defective repair response or recurrent injury may lead
to a repeated cycle of chronic inflammation. This is
modulated by various cytokines and growth factors,
including transforming growth factor-b (TGF-b) and
epidermal growth factor.28 These may illustrate why
corticosteroid inhibits most inflammatory effects in airwaysbut remodeling after recurrent injury still progresses. Since
corticosteroid does not inhibit the major mediators or
cytokines mentioned above, abnormal repair responses will
proceed after repeated episodes of asthma attack. In our
study, neither corticosteroid nor selective CysLT receptor
antagonist MK 679 alone could completely reverse effects
of airway remodeling. There have been reports of total
reversal of airway remodeling by CysLT1 receptor antago-
nist5; however, according to our results, selective LTD4
receptor antagonists such as MK-679 seem to be more
effective in modulating peribronchial fibrosis than cortico-
steroid, and may prevent further airway remodeling. More
recent studies have also demonstrated that CysLT receptor
antagonists can reverse established airway remodeling in
mice when the antagonist is first administered after the
development of allergen-induced airway remodeling. The
intervals of long-term follow-up, the time of treatment
intervention and different pathways of the acting CysLT
receptor antagonists may be the crucial factors that
differentiate results of our study from others.
In all studies to date, MMP-9 was the predominant MMP
in the airways of asthmatics. There are reports of increased
levels of MMP-2 and MMP-3 in sputum or BALF; however, the
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Figure 5 Effects of selective CysLT receptor blockade and
corticosteroid treatment on peribronchial collagen deposition.
Area of peribronchial collagen deposition was assessed by
Masson’s trichrome staining. Results are expressed as the area
of trichrome staining per micrometer length of basement
membrane. The results are expressed as means  SEM. N Z 7
in each group. *p < 0.05, compared with the all other groups.
yp < 0.05, compared with the OVA-treated sensitized group by
analysis of variance. CysLT Z cysteinyl leukotriene;
OVA Z ovalbumin.
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Figure 6 Expression of MMP-9 and MMP-2 in bronchoalveolar
lavage fluid: modulation by selective CysLT receptor blockade
and corticosteroid. (A) Levels of MMP-9 and MMP-2 were
assessed by zymography; (B) activity of MMP-9 was expressed
as relative density in each group; (C) activity of MMP-2 was
expressed as relative density in each group. The results are
expressed as means  SEM. N Z 7 in each group. *p < 0.05,
compared with the all other groups. yp < 0.05, compared with
the OVA-treated sensitized group by analysis of variance.
CysLT Z cysteinyl leukotriene; MMP Z matrix metal-
loproteinase; OVA Z ovalbumin.
242 C.-H. Hsu et allevels were considerably less than those of MMP-9. In our
study, both MMP-2 and MMP-9 were significantly increased
in OVA- sensitized/challenged mice. The levels of MMP-2
and 9 in BALF were proportional to the severity of airway
inflammation and the extent of airway remodeling.17 These
results were confirmed by serum IgE levels and pulmonary
histologic findings. Such change can be modulated after
effective treatment; therefore, MMP-2 and -9 may act as
more sensitive indices for monitoring the process of airway
remodeling. Interestingly, a distinctly different expression
of MMP-2 in BALF was noted between MK-679-treated and
Montelukast-treated OVA-sensitized/challenged mice (data
not shown). Inhibition of MMP-2 expression by MK-679 was
more effective than by Montelukast. This suggests a more
extensive action site (other than macrophages and eosino-
phils)9 of MK-679 than Montelukast, another CysLT receptor
antagonist.
Airway hyperresponsiveness to methacholine was
observed in OVA-treated mice. Both prednisolone and MK-
679 reversed airway hyperresponsiveness. However, such
suppressive effects disappeared in the MK-679 group when
challenged with higher doses of methacholine. It is possible
that although leukotrienes mediate the mucus release and
eosinophil infiltration of the airways, they do not control
the airway hyperresponsiveness of the late-phase asthma
response.20 The augmentation of growth factor-induced
human airway smooth muscle cells proliferation by leuko-
triene D4 is mediated by a CysLT receptor distinct from that
which mediates LTD4-induced airway contraction.29 Such
a characteristic may account for our unsatisfactory results
on inhibiting airway hyperresponsiveness by MK-679, in
spite of its effective actions on airway remodeling.
Increased airway thickness and airway contractile tissueswere supposed to positively correlate with airway hyper-
responsiveness in these studies.1,30 However, in other
models, dissociation or even negative relationship between
airway hyperresponsiveness and airway structure thickness
was obtained.5,31 Therefore, presumably, airway hyperre-
activity is mediated not just by structural changes but also
by multiple mediators and receptor distributions over
AB
Figure 7 Effects of selective CysLT receptor blockade and
corticosteroid treatment on pulmonary function to aerosolized
methacholine. The degree of bronchoconstriction [expressed
as Penh (% of air)] to aerosolized (A) low-dose (0 and 5 mg/ml)
or (B) high-dose methacholine (0, 5, 10 and 20 mg/ml) was
determined on Day 28 in saline-treated mice and OVA-treated
mice in the absence or presence of prednisolone or MK-679
treatment. The results are expressed as means  SEM. N Z 7
in each group. *p < 0.05, compared with all other groups
by analysis of variance. CysLT Z cysteinyl leukotriene;
OVA Z ovalbumin.
Cysteinyl leukotriene receptor antagonists 243airway smooth muscles and nerve fibers. These may explain
why corticosteroids seem more effective than MK-679 in
reversing airway hyperresponsiveness.
Clinically, airflow obstruction in asthma is often not fully
reversible, even with good management. The mechanisms
and factors involved in airway inflammation and remodeling
changes need to be determined in future studies, as well as
the therapeutical potential of MK-679 for treating asthma.
In summary, our results indicated that both corticoste-
roid and the selective CysLT receptor antagonists are
effective to some degree in preventing airway inflammation
and remodeling when they are treated during sensitization.
Corticosteroid was found to exert more significant effects
than the selective CysLT receptor antagonists on inhibition
of airway inflammation. In contrast, compared with corti-
costeroid, the selective CysLT receptor antagonists have
valid outcomes on reversal of airway remodeling in ananimal model of human asthma. These may not only suggest
CysLTs have different immunopathogenic pathways of
influencing on remodeling process that can not be modu-
lated by corticosteroid, but also display time-dependent
changes in the structures and functions of pulmonary
physiology. Long-term study on airway remodeling and the
influence of interventions during different pathogenic
periods will continue in the future. MK-679 needs more
studies to be used in clinical setting, too.Acknowledgments
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